Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-07
2005-06-07
Kemmerer, Elizabeth C. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S013800, C514S014800, C514S015800, C514S016700, C514S017400, C530S300000, C530S324000, C530S326000, C530S327000, C530S328000, C530S329000
Reexamination Certificate
active
06903068
ABSTRACT:
The present invention discloses a use of colostrinin, a constituent peptide thereof, and/or an analog thereof as an immunological regulator and as a blood cell regulator in animals including humans.
REFERENCES:
patent: 4938949 (1990-07-01), Borch et al.
patent: 5595887 (1997-01-01), Coolidge et al.
patent: 6040180 (2000-03-01), Johe
patent: 6410058 (2002-06-01), Gohlke et al.
patent: 6500798 (2002-12-01), Stanton et al.
patent: 2003/0091606 (2003-05-01), Stanton et al.
patent: 06 041191 (1994-02-01), None
patent: WO 95/00155 (1995-01-01), None
patent: WO 95/30686 (1995-11-01), None
patent: WO 98/14473 (1998-04-01), None
patent: WO 99/65329 (1999-12-01), None
patent: WO 00/75173 (2000-12-01), None
patent: WO 01/11937 (2001-02-01), None
patent: WO 01/12650 (2001-02-01), None
patent: WO 01/12651 (2001-02-01), None
patent: WO 02/13849 (2002-02-01), None
patent: WO 02/13850 (2002-02-01), None
patent: WO 02/13851 (2002-02-01), None
patent: WO 03/33423 (2003-10-01), None
Kruzel et al. (Dec. 2001) “Towards an Understanding of Biological Role of Colonstrinin Peptides.” Journal of Molecular Neuroscience 17(3): 379-389.
Inglot, Junsz, and Lisowski Colostrinine:a Proline-Rich Polypeptide from Ovine Colostrum Is a Modest Cytokine Inducer in Human Leukocytes, 1996, Archivum Immunologiae et Therapiae Experimentalis (44) 215-224.
Elgert, “Immunology: Understanding the Immune System” Text (1996) Wiley-Liss 1st Ed. pp. 24-26 and 199-217.
Ngo et al. Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox (1994) The Protein Folding Problem and Teriary Structure Prediction (#14), 491-495.
Wells Addivity of Mutational Effects in Proteins (1990) Biochemistry (29): 37, 8509-8517.
Babbit, ed.,The Vanderbilt Rubber Handbook,R.T. Vanderbilt Company, Inc., Norwalk, CT, pp. 344-397 (1978).
Bespalov et al., “Fabs specific for 8-oxoguanine: control of DNA binding,”J Mol Biol.Nov. 12, 1999;293(5):1085-95.
Blach-Olszewska et al., “Stimulatory effect of ovine colostrinine (a proline-rich polypeptide) on interferons and tumor necrosis factor production by murine resident peritoneal cells,”Arch Immunol Ther Exp(Warsz). 1997; 45(1):43-7.
Buescher et al., “Clostral antioxidants: separation and characterization of two activities in human colostrum,”J Pediatr Gastroenterol Nutr1. Jan. 1992; 14(1):47-56.
Calingasan et al., “Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease,”J. Neurochem.Feb. 1999;72(2):751-6.
Chao “Growth factor signaling: where is the specificity?”Cell.Mar. 20, 1992; 68(6):995-7.
Esterbauer et al., “Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes,”Free Radic Biol Med.1991;11(1):81-128.
Fields et al.,Synthetic Peptides: A User's Guide,W.M. Freeman & Company, New York, NY, pp. 77-183 (1992).
Fillmore et al., “Differentiation of PC12 cells with nerve growth factor is associated with induction of transin synthesis and release,”J Neurosci Res.Apr. 1992;31(4):662-9.
Gabbita et al., “Increased nuclear DNA oxidation in the brain in Alzheimer's disease,”J Neurochem.Nov. 1998;71(5):2034-40.
Gabbita et al., “Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain,”J Neurochem.Oct. 1999;73(4):1660-6.
Good et al., “Evidence of neuronal oxidative damage in Alzheimer's disease,”Am J Pathol.Jul. 1996;149(1):21-8.
Gratama et al., “Flow cytometric quantitation of immunofluorescence intensity: problems and perspectives. European Working Group on Clinical Cell Analysis,”Cytometry,Oct. 1, 1998;33(2):166-78.
Grunwald et al., “In situ analysis of chromatin proteins during development and cell differentiation using flow cytometry,”Methods Mol Biol.1999;119:443-54.
Hensley et al., “Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation,”J Neurochem.Nov. 1995; 65(5):2146-56.
Hughes et al., “Modulation of immune responses by anabolic androgenic steroids,”Int J Immunopharmacol.Nov. 1995;17(11):857-63.
Inglot et al., “Colostrinine: a proline-rich polypeptide from ovine colostrum is a modest cytokine inducer in human leukocytes,”Arch Immunol Ther Exp(Warsz). 1996;44(4):215-24.
Inglot et al., “Colostrinin for treatment of Alzheimer's disease,”European Cytokine Network.Sep. 1996;7(3):458(abstract 51).
Inglot et al., “Tumor-associated antigens are cytokine inducers and hyporeactivity factors to the immune system,”Biotherapy.1998;11(1):27-37.
Janusz et al., “Isolation and characterization of a proline-rich polypeptide from ovine colostrum,”FEBS Lett.Dec. 15, 1974;49(2):276-9.
Janusz et al., “Chemical and physical characterization of a proline-rich polypeptide from sheep colostrum,”Biochem J.Oct. 1, 1981;199(1):9-15.
Janusz et al., “Proline-rich polypeptide (PRP)—an immunomodulatory peptide from ovine colostrum,”Arch Immunol Ther Exp(Warsz). 1993;41(5-6):275-9.
Kim et al., “Simultaneous differentiation and quantitation of erythroblasts and white blood cells on a high throughput clinical haematology analyser,”Clin Lab Haematol.Feb. 1998;20(1):21-9.
Kooy et al., “Oxidation of 2′,7′-dichlorofluorescin by peroxynitrite,”Free Radic Res.Sep. 1997;27(3):245-54.
LeBel et al., “Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress,”Chem Res Toxicol.Mar.-Apr. 1992;5(2):227-31.
Leszek et al., “Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study,”Arch Immunol Ther Exp(Warsz). 1999;47(6):377-85.
Levi et al., “The mode of action of nerve growth factor in PC12 cells,”Mol Neurobiol.1988 Fall;2(3):201-26.
Lovell et al., “Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease,”Neurology.Aug. 1995; 45(8):1594-601.
Lovell et al., “Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease,”Neurobiol Aging.Sep.-Oct. 1997;18(5):457-61.
Lovell et al., “Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease,”Neurology.Dec. 1998;51(6):1562-6.
Lovell et al., “Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF,”J Neurochem.Feb. 1999;72(2):771-6.
Lovell et al., “Decreased base excision repair and increased helicase activity in Alzheimer's disease brain,”Brain Res.Feb. 7, 2000;855(1):116-23.
Markesberry, “Oxidative stress hypothesis in Alzheimer's disease,”Free Radic Biol Med.1997;23(1):134-47.
Markesbery et al., “Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease,”Neurobiol Aging.Jan.-Feb. 1998;19(1):33-6.
Markesbery et al. “Oxidative alterations in Alzheimer's disease,”Brain Pathol.Jan. 1999;9(1):133-46.
Marshall et al., “Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation,”Cell.Jan. 1995 27:80(2):179-85.
McHeyzer-Williams et al., “Enumeration and characterization of memory cells in the TH compartment,”Immunol Rev.Apr. 1996;150:5-21.
Mecocci et al., “Oxidative damage to mitochondrial DNA is Alzheimer's disease,”Ann Neurol.Nov. 1994;36(5):747-51.
Mishell et al.,Selected Methods in Cellular Immunology,W.H. Freeman, San Francisco, CA; title page and table of contents only, 9 pages (1980).
Montine et al., “Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease,”Ann Neurol.Sep. 1998;44(3):410-3.
Ostrea et al., “Influence of b
Boldogh Istvan
Georgiades Jerzy A.
Hughes, Jr. Thomas K.
Stanton G. John
Board of Regents , The University of Texas System
Kemmerer Elizabeth C.
Mueting Raasch & Gebhardt, P.A.
Nichols Christopher James
LandOfFree
Use of colostrinin, constituent peptides thereof, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of colostrinin, constituent peptides thereof, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of colostrinin, constituent peptides thereof, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3467904